西酞普兰联合阿立哌唑治疗抑郁症对照探究

《西酞普兰联合阿立哌唑治疗抑郁症对照探究》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、西駄普兰联合阿立哌坐治疗抑郁症对照探【摘要】目的探讨西駄普兰联合阿立哌哇治疗抑郁症的临床疗效及安全性。方法将61例抑郁症患者随机分为两组，均给予西駄普兰治疗，研究组联合阿立哌哩治疗,观察8Wo于治疗前及治疗第1w、2w、4w、6w、8w末采用汉密顿抑郁量表、临床疗效总评量表、副反应量表评定临床疗效和不良反应。结果研究组治疗5d〜19d显效，对照组13d〜31d显效，两组比较有显著性差异（t=2.25,P＜0.05）；汉密顿抑郁量表评分研究组治疗1w末起，对照组2w末起较治疗前有极显著性下降（PV0.01）,且随治疗时间的延续均呈持续性下降；研究组治疗1w、2w、4w、6w末较对照

2、组下降显著（P均＜0.05）,治疗8w末无显著性差异（P均〉0.05）；临床疗效总评量表评分，治疗8w末两组均较治疗前有极显著性下降（卩均＜0.01）；两组不良反应均轻微。结论西駄普兰联合小剂量阿立哌哩治疗抑郁症疗效显著，起效快，安全性高，依从性好。【关键词】抑郁症；西駄普兰；阿立哌哇[Abstract]ObjectiveToexploretheclinicalefficacyandsafetyofcitalopramcombinedwitharipiprazoleinthetreatmentofdepression.MethodsSixtyonedepressivepatien

3、tswererandomlyassignedtoresearchreceivingcitalopramcombinedwitharipiprazoleandcontrolgroupdoingcitalopramfor8weeks,clinicalefficacieswereassessedwiththeHamiltonDepressionScale(HAMD)andtheClinicalGlobalImpression(CGI)andadverseeffectswiththeTreatmentEmergentSymptomScale(TESS)beforetreatmentand

4、attheendsofthe1st,2nd,4th,6thand8thweektreatment・ResultsTheresearchgrouptookeffectswithin5〜9daysandthecontroldid13〜31days,whichshowedsignificantdifference(P<；0.05)；comparedwithpretreatment,theHAMDscoreloweredverymoresignificxantlyintheresearchsincetheendofthe1stweekandinthecontrolsincethe2n

5、d(P<；0.01),andcontinouslydidalongwithtreatmentlasting；attheendsofthe1st,2nd,4thand6thweekthecontrolloweredmoresignificantlythantheresearchdid(P<；0.05),attheendofthe8thweektherewasnodifferncebetweenthe2groups(P>；0.05)；theCGIscoresofbothgroupsloweredverymoresignificantlyattheendofthe8thwe

6、ekcomparedwithpretreatment(P<；0.01)・Adverseeffectsofbothgroupsweremilder・ConclusionCitalopramcombinedwithsmalldosearipiprazoletakeseffectsfasterandhasmoersignficantefficacy,highersafetyandbettercomplianceinthetreatmentofdepression.[Keywords]Depression；citalopram；aripiprazol西駄普兰治疗抑郁症已取得较好的疗效

7、，但西駄普兰起效相对较慢，通常为2w,部分患者需达4w才能显效[1]。药物起效快慢有可能影响患者的服药依从性，因为绝大多数患者希望在接受治疗后短期内能迅速显效，部分患者可因短期内未显效而放弃治疗。为此，我们采用西駄普兰联合小剂量阿立哌吐治疗抑郁症进行了对照研究，评价其治疗抑郁症起效时间，临床疗效及安全性。1对象与方法1.1对象选取2006年3月〜12月在我院门诊和住院治疗的抑郁症患者为研究对象。入组标准：（1）符合《中国精神障碍分类与诊断标准》第3版（CCMD3）抑郁症诊断标准。